



CONCURRENT PACLITAXEL AND RADIATION THERAPY IN CISPLATIN CONTRAINDICATED LOCALLY ADVANCED HEAD AND NECK CANCER – A PROSPECTIVE STUDY

Oncology

Dr Rajat Bandyopadhyay*

Associate Professor, Department. of Radiotherapy, Burdwan Medical College, Purba Bardhaman, West Bengal. *Corresponding Author

Dr Suparna Banerjee

Assistant Professor, Department. of Pathology, Diamond Harbour Govt. Medical College, Diamond Harbour, West Bengal.

ABSTRACT

Concurrent chemoradiation with Cisplatin is the standard of care in locally advanced head and neck cancer. The present study was done with Paclitaxel, a potent radiosensitiser in Cisplatin contraindicated patients. Fifty patients of non-metastatic locally advanced squamous cell carcinoma in whom cisplatin was contraindicated were divided into two arms. Arm 1 received weekly Paclitaxel 40mg/m² along with External Beam Radiotherapy. Arm 2 received Ext RT only. In the combined arm 60% showed complete response (CR) whereas 20% had partial response (PR) with a total response of 80%. In the RT only arm 40% had CR and 20% had PR with total response of 60%. Grade II/III mucositis the major toxicity was seen in 88% cases in combined against 36% in the single arm. Concurrent Paclitaxel + RT showed excellent results with increased toxicity.

KEYWORDS

Head and Neck cancer, Concurrent Chemoradiotherapy, Paclitaxel

Squamous cell cancer of the head neck is the commonest solid cancer among adult males in India¹. Standard local therapy – Radiation or Surgery alone yields poor results in locally advanced head and neck cancer². Chemotherapy alone is also not satisfactory but it enhances the effects of RT and is routinely used as part of combined modality treatment in patients with Stage III or IV disease³. Concurrent Chemoradiation with Cisplatin is the standard care now. There is no standard drug for concurrent chemoradiation in patients with contraindications to Cisplatin. Radiation potentiation is an additional desirable benefit of some anti-cancer drugs. They increase cell kill by reducing the clonogenic cell numbers both inside and outside the radiation field. Some drugs directly sensitise the tumour cells to radiation further increasing cell kill. Paclitaxel is a potent radiosensitiser that has major anti-neoplastic activity. It has excellent radiosensitisation property by cell blockage in G2/M phase. Concurrent chemoradiation with Paclitaxel results in greater response than radiation alone⁴. The present study was undertaken to see the effects of concurrent Paclitaxel chemoradiation in cisplatin contraindicated locally advanced head and neck cancer on locoregional control and acute toxicities.

MATERIALS AND METHODS

The prospective comparative study was done in the Department of Radiotherapy, Medical College, Kolkata from July 2006 to June 2007. Fifty previously untreated Stage III/IV squamous cell cancer of head and neck with ECOG performance 0-3, no distant metastasis and in whom Cisplatin was contraindicated were selected and randomised into two arms. Study arm of concomitant Paclitaxel chemoradiation (25 patients) and control arm of only radiation (25 patients). Patients with severe comorbid medical illness were excluded. External Beam Radiotherapy was delivered using Telecobalt machine to primary and draining lymph nodes to a total dose of 66 to 70 Gray in 33 to 35 fractions over 6 - 7 weeks, with field shrinkage and sparing of spinal cord after 44 Gray. Study arm (Arm 1) received Paclitaxel 40mg/m² one hourly infusion one hour before radiation weekly IV on days -D₁, D₈, D₁₅, D₂₂, D₂₉, D₃₆. Arm 2 received only radiation. During treatment patients were monitored for haematologic toxicities and radiation reactions weekly. After treatment completion follow up was done after 2 weeks and thereafter monthly for a median follow up of six months.

RESULTS AND ANALYSIS

The patients in both the arms were comparable in terms of sex, staging & disease sites. All the fifty patients completed their treatment as planned and were evaluable. In the Arm 1 (Paclitaxel + RT) 15 patients achieved complete response (60%) and 5 patients (20%) had a partial response for an overall response of 80%. On a median follow up of 6 months 5 patients progressed out of which one died. In the Arm 2 (RT only) 10 patients had complete response (40%) while 5 patients (20%) had partial response giving an overall response of 60%. As many as 10 patients (40%) on radiation only showed no response and progressed.

Table 1: Treatment Response

RESPONSE	Arm 1 (n=25) Paclitaxel+ RT	Arm 2 (n=25) RT only
Complete Response (CR)	15 (60%)	10 (40%)
Partial Response (PR)	5 (20%)	5 (20%)
Total Response CR + PR	20 (80%)	15 (60%)
No Response	5 (20%)	10 (40%)

Mucositis was the most commonly encountered toxicity in both the arms. Mucositis was more severe in the combined arm where 88% of the patients developed Grade II or Grade III mucositis by the end of 6 weeks. Mucositis was observed from 2nd weeks onwards. Grade II dermatitis developed in 5 patients of Arm I. No patient had Grade III Neutropenia. In the RT only arm only 36% of the patients developed Grade II or III mucositis. No patient required discontinuation of treatment in either arm.

Table 2: Toxicities – Mucositis

	ARM 1			ARM 2		
Weeks	Grade I	Grade II	Grade III	Grade I	Grade II	Grade III
2 nd week	5 (20%)	0	0	0	0	0
3 rd week	15 (60%)	5 (20%)	0	5 (20%)	0	0
4 th week	18 (72%)	7 (28%)	0	10 (40%)	0	0
5 th week	7 (28%)	13 (52%)	5 (20%)	13 (52%)	5 (20%)	0
6 th & 7 th week	3 (12%)	15 (60%)	7 (28%)	15 (60%)	7 (28%)	2 (8%)

DISCUSSION

Locally advanced head and neck cancer is treated by concurrent cisplatin based chemoradiation which is now the standard of care. Problem arises in patients with contra indication for cisplatin. There is no standard concurrent drug for this group of patients. Paclitaxel based concurrent chemoradiation is an attempt to achieve higher response than radiation alone with acceptable toxicities in those patients. Paclitaxel has been used in low dose because of clinical data of its powerful antitumor and radio sensitization effect. Essa et al⁵ studied 41 patients, 21 with concurrent Paclitaxel 30mg/m² weekly and 20 patients with concurrent Cisplatin 30 mg/m² with RT to a dose of 66-70 Gray in conventional fractionation. CR was seen in 57.1% in group I & 50% of group II while PR was seen in 28.6% in group I & 25% in group II. Objective Overall response was 85.7% in group I versus 75% in Group II with no statistical significance. Treatment toxicities were comparable in both groups. The authors concluded that concurrent chemoradiotherapy with weekly paclitaxel was feasible when cisplatin was contraindicated. Citrin D et al⁶ studied 35 patients with locally advanced squamous cell carcinoma of head & neck who received 120 h infusion of Paclitaxel on Day 1, 21 & 42 along with conventional fractionated radiotherapy. Initial 16 patients received 105 mg/m² and the later 19 patients received 120 mg/m²/cycle. At a median follow up of 56.5 months median time to local recurrence was not reached. The

authors concluded that concurrent chemoradiotherapy with a 120h infusion of paclitaxel provided long term local control and survival in patients with squamous cell carcinoma of head and neck cancer with acceptable toxicities. Agarwala SS et al⁷ conducted a phase II trial in inoperable locally advanced SCCHN with Carboplatin 100mg/m² and paclitaxel 40mg/m² weekly during external beam radiation (180 cGy per fraction) for 6-7 weeks. 40 of the 50 assessable patients (80%) had an objective response with a complete response of 52%. The authors concluded that treatment with concurrent carboplatin, paclitaxel and radiation was safe and offered curative potential for poor prognosis patients with locally advanced head and neck cancer. Sunwoo J B et al⁸ carried out a study with 33 patients with concurrent paclitaxel 120-hour infusion 3 weekly and radiation. 16 patients received 105mg/m² and 17 patients received 120mg/m². Radiation was delivered at 1.8 Gy/day to a total dose of 70.2 to 72 Gy. At 3 months 76% complete response was obtained at primary site. At 36 months locoregional control was 55.75, overall survival was 57.8% and disease-free survival was 51.1%. The authors concluded that paclitaxel administered as a 120-hr continuous infusion in combination with radiotherapy is a feasible and promising treatment for patients with advanced HNSCC. Maring S⁹ et al analysed 104 patients with LASCCHN treated with radiochemotherapy between 2013 & 2018. 81 patients (78%) received cisplatin while 23(22%) got carboplatin paclitaxel. The rate of recurrence was 38% in the cisplatin RT arm & 30% in the paclitaxel carboplatin RT arm. (p- 0.6) and overall survival was 35 versus 28 months in cisplatin versus paclitaxel arm (p- 0.5). Significantly higher Grade III/IV toxicity was seen in the cisplatin RT arm (p- 0.002). The authors concluded that RCXT with paclitaxel carboplatin was safe and effective treatment alternative for LASCCHN patients with contraindication for cisplatin based RCXT. Bera A, Banerjee C et al¹⁰ studied 98 patients 2014 & 2018 with locally advanced SCC carcinoma of head and neck treated with 40mg/m² paclitaxel with radiation to dose of 66 Gray in conventional fractions. Overall complete response (CR) rate was seen in 68% patients and partial response was seen in 32% patients. Two year disease free survival, progression free survival, and overall survival were 59%, 72% and 85% respectively. The authors opine that CRT with paclitaxel in locally advanced head and neck cancer was safe and conferred high CR rate with acceptable toxicity. Our study is in agreement with the other studies. 80% of our patients on concurrent weekly paclitaxel based chemoradiotherapy achieved overall response as compared to 60% with radiation only arm which is statistically significant. As expected, toxicity especially mucosal toxicity was much higher in the combined arm with 88% having Grade II/III toxicity in contrast to 36% Grade II/III toxicity in RT only arm, (statistically significant). The toxicities were manageable and there was no treatment disruption.

CONCLUSION

Treatment of locally advanced squamous cell carcinoma of head and neck cancer with concomitant weekly paclitaxel and external beam radiotherapy is feasible in cisplatin contraindicated patients and shows excellent results when compared to radiotherapy alone with acceptable toxicity.

Further study with more patients and longer follow-up is necessary.

REFERENCES

1. Park's Text Book of Preventive & Social Medicine: K Park 15th Edition, Pp 205.
2. Chougule P, Wanebo H et al: Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long term follow-up of a Brown university Oncology Group Phase II Study, Head Neck. 2008 Mar.
3. Mendenhall W M et al in Cancer: Principles & Practice of Oncology: Ed. De Vita, Hellman & Rosenberg Ch 38 Pp 424.
4. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: Preclinical studies. Semin Radiat Oncol 1999;9:12-26. 27. Kanotra SP, Ka
5. Essa et al: Concurrent chemoradiation in locally advanced head and neck cancers: a comparative study of weekly Paclitaxel versus Cisplatin-based regimen: J Egypt Natl Canc Inst. 2010 Sep.
6. Citrin D et al: Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer: Int J Radiat Oncol Biol Phys. 2009 Jul 15.
7. Agarwala S S: Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer: Ann Oncol. 2007 Jul.
8. Sunwoo John B et al: Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer: Jour of Clin Oncol Vol 19 Issue 3.
9. Maring S et al: Efficacy of Carboplatin/Paclitaxel Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck: Oncol Res Treat 2018;41:736-742
10. Bera A, Banerjee S et al: Concurrent chemoradiation with paclitaxel in locally advanced head and neck cancer: a feasibility study from tertiary care center. Int Jour Med Sc & Pub Health. 2019 Nov;8(11):991-995